Darvadstrocel - TiGenix

Drug Profile

Darvadstrocel - TiGenix

Alternative Names: Alofisel; Cx-601

Latest Information Update: 18 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellerix
  • Developer La Fundacion para la Investigacion Biomedica del Hospital Universitario La Paz; Takeda; TiGenix
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rectal fistula
  • New Molecular Entity No

Highest Development Phases

  • Registered Rectal fistula
  • No development reported Rectovaginal fistula; Ulcerative colitis

Most Recent Events

  • 18 Oct 2018 Takeda plans a phase III trial for Rectal fistulas in Japan , (JapicCTI-184145)
  • 31 Jul 2018 TiGenix has been acquired by Takeda
  • 29 Mar 2018 No development reported - Phase-I/II for Ulcerative colitis in Spain (Submucosal) (NCT01914887)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top